The Claim
Plasma p-tau217 levels are significantly higher in individuals with amyloid-PET positivity (Centiloid > 20) than in those without amyloid-PET positivity, and plasma p-tau217 demonstrates greater diagnostic separation between these groups than plasma Aβ42/40, GFAP, or NfL.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people with confirmed brain amyloid buildup, plasma levels of p-tau217 are higher than in those without amyloid buildup, and p-tau217 distinguishes these groups more clearly than other blood biomarkers like Aβ42/40, GFAP, or NfL.
See the scientific wording
Plasma p-tau217 levels are significantly higher in individuals with amyloid-PET positivity (Centiloid > 20) compared to those without, and the biomarker shows greater separation between groups than plasma Aβ42/40, GFAP, or NfL.
When abnormal clumps of amyloid build up in the brain, they cause neurons to overactivate enzymes that add phosphate groups to tau protein at a specific spot called threonine 217. This modified tau, called p-tau217, leaks out of neurons into the fluid around the brain and then into the bloodstream, where it can be measured. Other blood markers do not rise as specifically or as strongly because they are not directly tied to this exact molecular change in neurons.
What the research says
1 studyPeople with Alzheimer’s brain plaques have much higher levels of a specific protein (p-tau217) in their blood than those without plaques, and this blood test is better at telling them apart than other common blood tests.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.